Vensana Capital has successfully wrapped up a $425 million Fund III to further invest in pioneering medtech firms. Based in Edina, Minnesota, the venture capital firm disclosed yesterday that it now manages approximately $1 billion in assets.
This development is likely to inject some optimism into the current medtech funding landscape, which has been experiencing mixed results, despite a rise in exit opportunities via mergers, acquisitions, and IPOs. DeviceTalks Editorial Director Tom Salemi is set to host a DeviceTalks Tuesday webinar with HSBC Managing Director Jonathan Norris at 12 p.m. ET on January 23, 2025, focusing on this year’s medtech funding outlook. Register here for the complimentary webinar.
Since its inception in 2019 by Kirk Nielsen and Dr. Justin Klein, Vensana Capital has collaborated with over 20 companies, achieving six exits worth nearly $3 billion in total. These exits include the acquisitions of Artelon (by Stryker), Intact Vascular (by Philips), Relievant Medsystems (by Boston Scientific), Personal Genome Diagnostics, and Vesper Medical (by Philips), along with CVRx’s initial public offering.
“We take immense pride in the strides Vensana has made since its inception, as we diligently strive to construct a leading medtech investment and company-building framework. We deeply appreciate the unwavering support of our limited partners,” expressed Nielsen, a managing partner at Vensana Capital, in a press statement.
Klein, also a managing partner, shared: “Our team is thrilled about the road ahead as we maintain collaborations with innovators who are reshaping healthcare through revolutionary medical technology. We’re keenly aware of the significance our work has on our limited partners, our portfolio companies and their teams, and—above all—on our clinician partners and their patients.”